Hemorrhagic Bullous Dermatosis Associated With Low Molecular Weight Heparin: A Case Report

Güldaval, Filiz; Yavuz, Melike Yüksel; Anar, Ceyda; Alıcı, İbrahim Onur; Tunçok, Sedat; Ermete, Sülün; Büyükşirin, Melih

doi:10.5222/terh.2018.131

Cited by 1 publication

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One patient developed BHD after enoxaparin administration, but UFHs could be used safely [12]. While there may be cross-reaction between low molecular weight heparin, one patient developed BHD after using enoxaparin and one patient also developed hemorrhagic blistered skin disease after continuing to use tinzaparin [13]. LMWH may also cross-react with fondaparinux.…”

Section: Discussionmentioning

confidence: 99%

Clinical Features, Diagnosis, Treatment, and Prognosis of Heparin‐Induced Bullous Hemorrhagic Dermatosis

Li,

Peng,

Zhang

et al. 2024

Dermatologic Therapy

View full text Add to dashboard Cite

Background. Heparin-induced bullous hemorrhagic dermatosis (HBHD) is a rare cutaneous adverse effect of heparin and has unclear clinical features. We explored the clinical features of HBHD to provide evidence for the safe use of heparin. Methods. We collected HBHD-related case reports for a retrospective analysis by searching the Chinese and English databases from inception to December 31, 2022. Results. Seventy-two patients, including 51 males (70.8%), were included, and they had a median age of 71.5 years (range: 21, 94). Low-molecular-weight heparin was used in 62 patients (86.1%), and unfractionated heparin was used in 10 patients (13.9%). The median time for HBHD to appear was 7 days (range: 0.25, 270). Lesions appeared far from the injection site, and the extremities (57 patients, 79.2%) were the most frequently involved site. The blisters were mainly located in the intraepidermal (34 patients, 47.2%), subcorneal (10 patients, 13.9%), and subepidermal (9 patients, 12.5%) regions. Thirty-seven patients (51.4%) had no obvious dermal inflammatory infiltration, and 20 patients (27.8%) had lymphocytic inflammatory infiltration. Sixty-seven patients (93.1%) recovered from their skin lesions after the discontinuation of heparin or despite continuing heparin and at a median treatment time of 14 days (range: 2, 141). Conclusion. HBHD is a rare self-limiting disease that occurs far from the injection site. Clinicians should be aware of BHD during the administration of heparin. Heparin can be discontinued or continued depending on the patient’s condition.

show abstract

Section: Discussionmentioning

confidence: 99%